Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Charles River on Its Acquisition of MPI Research
Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI…
Seattle Genetics, Inc. $600 Million Equity Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC…
Varian Medical Systems Acquires Sirtex Medical
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Varian Medical Systems, Inc. in connection with…
Solid Biosciences Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $133.7 million initial public offering of common…
ConforMIS, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the SEC…
Five Prime Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897…
Adamas Pharmaceuticals, Inc. Common Stock Follow-On Offering
Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
Agios Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
BeiGene, Ltd. $800 Million Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public…